.jpg?w=340&itok=vvIkDfgO "IPT discussed in technical publications."){kind=icon}
Participant-centric study design has advanced, but site-centric execution has not kept pace. In the Journal for Clinical Studies, Brian Mallon examines how unclear expectations, administrative burden and contract delays ...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
.jpg?w=545&itok=7luDTQY4 "IPT discussed in technical publications.")
Providing support throughout the patient journey
Concierge services are critical to helping patients navigate technology and other logistics in a decentralised clinical trial. Laney Preheim outlines how they can best be implemented.
This article is taken fromInnovations in Pharmaceutical Technology, October 2022, pages 34-36 . Samedan Ltd
-
What Biotech and Pharma need to consider about decentralised trials
Discuss key considerations when implementing decentralised clinical trials, in addition to the success factors that lead to more patient-centric trials and increased patient recruitment, engagement and retention.
-
The surge of digital health technologies modernising clinical research
Dr. Isaac R. Rodriguez-Chavez outlines the key considerations when developing digital health technologies.
-
The innovative 'digiverse' that's propelling transformative decentralised clinical trials
Dr. Isaac R. Rodriguez-Chavez offers his insights on the use of innovative digital health technologies and digital ecosystems to support decentralised clinical trials.
International Clinical Trials, May 2022, pages 54-57. Samedan Ltd
-
Identifying integrated digital platforms designed for a decentralised future
Matt Harrington, VP of Connected Health Technology Solutions, explores how the use of digital platforms and associated services can contribute to more adaptable, accessible and efficient clinical trials.
-
JPM 2022: Decentralised trials, broader service offerings and novel drugs key trends in the CRO space
In this snapshot from the J.P. Morgan Healthcare Conference, Steve Cutler comments on ICON’s success in decentralised trials and therapeutic technologies such as mRNA and checkpoint inhibitors.
-
In-Home Services: A patient-centric approach to improving recruitment and retention in clinical trials
Advances in wearables, telemedicine and remote monitoring technology along with the convenience of in-home visits were bound to make decentralised and hybrid clinical trials standard with enough time. However, the COVID-19 pandemic accelerated their adoption and now, even with the hope that the pandemic will soon be behind us, hybrid and decentralised models are poised to become viable solutions in clinical trial design because of their inherent agility, inclusivity and most importantly, patient centricity.
-
Capture, curate, consume: The three Cs of managing data in decentralised and hybrid clinical trials
Emily Mitchell, Executive Director, Decentralised Clinical Trials Operations and Christina Dinger, Director, Decentralised Clinical Trials Operations, run through some of the most important elements of collating and organising data during clinical trials.
This article was taken from Pharmafocus December 2021, pages 16-17. Samedan Ltd.
-
ICON expands Accellacare Site Network
An article reporting on ICON's recent announcement that its Accellacare Site Network has entered new partnerships with six research sites across four countries, expanding its global footprint and capabilities.
-
